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Table
Characteristics and outcomes of the participants (n¼409)
Variable No. (%) Mean  SD
Age, yr 52.3  12.3
Range 18.2 d 75.2
Male 257 (63)
KPS 86  6
6MWD, m 404 113
Range 71 d 737
EF 62  5
ECHO 297 (73)
MUGA 105 (26)
Other 4 (1)
Unavailable 3 (>1)
DLCO 82.4  17.97
Tumor type d no. (%)
AML 150 (37)
ALL 32 (8)
Other acute leukemia 5 (1)
CML 13 (3)
NHL/CLL 104 (25)
HD 13 (3)
MDS/MPD 54 (13)
MM 35 (9)
Other 3 (1)
1st Allogenic transplant 401 (98)
Conditioning regimen intensity
MA 266 (65)
Rl 69 (17)
NMA 74 (18)
Donor type
Matched related 139 (34)
Mismatched related 1 (<1>
Matched unrelated 147 (36)
Mismatched unrelated 62 (15)
Cord or cord/haplo 60 (15)
Source
Bone marrow 12 (3)
Peripheral blood 337 (82)
Cord or cord/haplo 60 (15)
Manipulation
Unmodiﬁed 140 (34)
TCD 209 (51)
Cord or cord/haplo 60 (15)
Follow up for survivors, months 35  15
Range 3 d 61
Relapse 70 (17)
Causes of death
Relapse 70 (40)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53 S33These high risk class 3 also received hydroxyurea 20 mg/kg/
d for at least 3 months prior to HSCT. All pts received 2
courses of pre-transplant immunosuppression (PTIS) con-
sisting of ﬂudarabine (Flu) 40 mg/m2/d together with dexa-
methasone (dex) 25 mg/m2/d for 5 days. After 2 courses of
PTIS, all pts received a reduced-toxicity conditioning
regimen consisting of thymoglobulin 1.5 mg/kg/d (d-11 to
d-9), Flu 35 mg/m2/d i.v. (-7 to -2) each dose immediately
followed by busulfan (Bu) 130 mg/m2once daily i.v. (d-7 to
d-4) for pts > 10 years and 0.95-1.2 mg/kg every 6 hr (d-7 to
d-4) for pts < 10 yrs. GVHD prophylaxis consisted of cyclo-
phosphamide (Cy) 50 mg/kg/d (d+3 to d+4). Tacrolimus was
given for 6 months to 1 yr started together with mycophe-
nolate mofetil on d+5, the latter was quickly tapered after 2
months. T-cell repleted peripheral blood stem cells were
given to all pts targeting a CD34+ dose of 7-10 x 106 cells/kg.
Results: Fourteen of 15 were engrafted with full donor
chimerism (100%) while one pt suffered graft failure. How-
ever, this pt received second transplant on day +30 with
minimal conditioning regimen and additional PBSC, after
which she achieved full donor chimerism. The median time to
neutrophil engraftment was 18 days (range; 14 -22). Six pts
had acute GVHD gr I, 3 grade II and1 gr III. Only one had
limited chronic GVHD. At this time, all 15 pts survive thalas-
semia-free and have sustained full donor chimerism (100%).
The thalassemia free survival and overall survival rates are
100%. Themedian follow up timewas 12months (range 4-22).
Conclusion: Haplo-SCT for high risk thalassemia pts with
our novel approach is safe, and should be considered as a
modality to secure thalassemia-free survival with a low risk
of graft rejection and treatment-related mortality. With this
result, our Haplo-SCT in thalassemia pts has favorable
outcome as related and unrelated HSCT (thalassemia free
survival rate> 90%). In viewof our results, we suggest that all
thalassemia pts even those with high risk class 3 features
should be offered the chance for cure with HSCT.
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Prognostic Importance of Functional Capacity for Pre-
Transplant Risk Assessment Among Patients Undergoing
Allogeneic Hematopoietic Cell Transplantation
Lee W. Jones 1, Sean Devlin 2, Molly Malroy 1,
Noel Espiritu 1, Jennifer Aquino 1, Ceceile Hall 1,GvHD 46 (26)
Infection 30 (17)
Graft failure 7 (4)
Toxicity 3 (2)
Other 18 (10)
Abbreviations: BMI, body mass index; KPS, Karnofsky Performance Sta-
tus; 6MWD, six minute walk distance; AML, Acute Myelogenous Leuke-
mia; ALL, Acute Lymphoblastic Leukemia; CML, Chronic Myelogenous
Leukemia; NHL/CLL, Non Hodgkin Lymphoma/Chronic Lymphocytic Leu-
kemia; HD, Hodgkin Lymphoma, MDS/MPD, Myelodysplastic Syndrome/
Myeloproliferative Disorder; MM, Multiple Myeloma; MA, Myeloablative;
RI, Reduced Intensity; NMA, Non Myeloablative; TCD, T Cell Depleted.
Figure . Cumulative incidence of overall survival according to six-minute walk
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Background: Identiﬁcation of patients at high risk of he-
matopoietic cell transplantation (HCT)-related complications
Figure 1. Cumulative incidence of grade 3-4 aGVHD among BM (A) and PBSC
recipients (B).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S34is of major clinical importance. Exercise-based assessments
provide a quantitative measure of physical functioning not
captured by traditional resting parameters. We investi-
gated whether functional capacity predicted mortality af-
ter HCT.
Patients and Methods: Using a prospective design, 409
patients completed a six-minute walk distance test
(6MWD) prior to undergoing HCT. 6MWDs were obtained
within 5 days of transplant admission; carbon monoxide
diffusing capacity (DLCO) and left ventricular ejection frac-
tion (LVEF) were determined within 1 month of admission,
Karnofsky performance status (KPS) was reported imme-
diately prior to admission and hemoglobin (Hgb) was ob-
tained on the day of transplant. Cox proportional hazards
regressionwere used to estimate the risk of mortality due to
relapse or progression of disease (RM), non-relapse mor-
tality (NRM), and overall survival (OS) according to 6MWD
(<400 m versus 400 m) with adjustment for cardiovas-
cular risk factors.
Results: Participant characteristics are presented in the
Table. Mean 6MWD was 404  113 m (range: 71 to 737 m).
Median follow-up was 36 months (range 3 to 61 months).
During this period, 43% patients died (n¼104, NRM). In
univariate analyses, 6MWD predicted NRM (p¼0.025) and
OS (p¼0.028; Figure), but not RM (p¼0.468). Compared
with patients achieving a 6MWD <400 m, the unadjusted
hazard ratio (HR) for NRM and OS was 0.64 (95% CI,
0.44e0.95) and 0.72 (95% CI, 0.53e0.96), respectively for
those achieving 400 m. In multivariable analyses, the
relationship between 6MWD and NRM and OS became non-
signiﬁcant after adjustment for KPS, DLCO, and Hgb con-
centration. LVEF did not predict any post-HCT outcomes
(p’s>0.05).
Conclusions: Although 6MWD was not an independent
predictor of post-HCT outcomes, the strong univariate asso-
ciation with NRM and OS suggests further investigation of
alternative measures of physical functioning (e.g., exercise
capacity) are warranted.13
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(aGVHD) after HLA-matched sibling bone marrow (BM)
allogeneic hematopoietic cell transplantation (alloHCT) is
lower in the Japanese than the Caucasians (Blood 2005,
105:1408). However, the impact of race on aGVHD might
differ according to graft source (BM versus peripheral blood
stem cell (PBSC)) in HLA-matched sibling alloHCT. To test this
hypothesis, we analyzed data from the Center for Interna-
tional Blood and Marrow Transplant Research and the Japan
Society for Hematopoietic Cell Transplantation.
Methods: North American Caucasian and Japanese patients
who received their ﬁrst allogeneic BM or PBSC alloHCT from
HLA-matched sibling for acute leukemia in complete remis-
sion or chronic leukemia in chronic or accelerated phase
between 2000 and 2011 were eligible. Patients were 18 - 59
years old, received myeloablative conditioning regimen, and
used cyclosporine or tacrolimus-based GVHD prophylaxis.
Effect of race (Caucasian vs. Japanese), graft source (BM vs.
PBSC), and their interaction on transplant outcomes was
evaluated in the Cox proportional hazards model adjusting
for other signiﬁcant variables.
Results: Median ages of Caucasians and Japanese patients
were 45 and 38 years, respectively. BMwas used in 13% of the
Caucasians, whereas it was used in 53% of the Japanese. Cor-
responding rates of tacrolimus-based GVHD prophylaxis
were 68% and 7%. The cumulative incidence of grade 3-4
aGVHD at 100 days post BM alloHCT was 10% and 6% in the
Caucasians and Japanese, respectively (Figure 1A), and that of
